Allurion added to Deloitte List of Fastest Growing Companies
Company reports 444% revenue growth from 2018 to 2021 and has also been named as one of MedTech Outlook’s Top 10 Medtech Compani
NATICK, Mass, November 16, 2022 — Allurion, a company dedicated to ending obesity, today announced it was named to the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.
Technology Fast 500 awardees are selected based on percentage fiscal year revenue growth from 2018 to 2021. Allurion grew 444% during this period.
Allurion Founder and Chief Executive Officer, Dr. Shantanu Gaur, attributes the company’s rapid growth to the size of the market opportunity, Allurion’s game-changing innovations, and best-in-class team.
“We are proud of the rapid growth we have delivered in such a short period of time and have an exciting pipeline of innovations that will continue to fuel future expansion,” he said.
“Allurion’s success is a testament to the quality and caliber of our entire team and their commitment to our mission to end obesity around the world.”
Allurion is also announcing today that it has been named one of MedTech Outlook’s “Top 10 Medtech Companies in Europe 2022.”
The annual listing recognizes 10 startups in Europe that are at the forefront of providing medtech solutions and transforming businesses in the region.
Allurion Chief Commercial Officer, Benoit Chardon, said the international ranking and award recognizes Allurion’s audacious approach to innovation.
“This award not only acknowledges Allurion’s innovative approach to creating the world’s first full stack weight-loss platform but also the tremendous growth the company has experienced,” he said.
“Allurion has become a strong global brand while pioneering the future of non-invasive medical weight loss.
With more than 100,000 patients treated in 60 countries, we are well-positioned to penetrate new markets and help millions of people create a healthier future with our holistic weight loss program.”
About the 2022 Deloitte Technology Fast 500™
Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2018 to 2021.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
Learn more about Allurion online at www.allurion.com.
Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.
* In rare cases, the Allurion Balloon may require endoscopic or surgical intervention for removal.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
Media Contact
Cedric Damour
PR Manager
+33 7 84 21 02 20
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and...
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15%...
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion...
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
In a...
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion...
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to its Board of Directors
Mr. Johns has...
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight...
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for...
Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer
NATICK, Mass. -- June 5, 2024 -- ...
Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s
Company also announces first...
Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean...
Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including
First-Ever 3-Year...
Allurion Expands Virtual Care Suite to the United States
Virtual Care Suite (VCS) is now available to license...
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies
NATICK, Mass. -- Jan. 29, 2024 -- Alluri...
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
Allurion...
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic...
Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4...
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion...
Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership
Company also announces addition...
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon
AUDACITY trial to support FDA...
Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023
Research highlights...
Allurion Featured at the 2023 International Bariatric Club
Oxford University World Congress
Congress...
Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach
Powered by GPT and Fine-Tuned...
Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress
New data includes...
Allurion Debuts as a Publicly Traded Company on the NYSE
Allurion to commence trading on August 2, 2023 on the...
Allurion Announces New Additions to Board of Directors and Executive Leadership Team
Serial healthcare...
Allurion Presents New Data at the 2023 ASMBS Annual Meeting Demonstrating Mean Weight Reduction of Over 20%
P...
Allurion Announces Collaboration Agreement with Medtronic to Expand Access to AI-Powered Weight Loss Program
...Allurion to Participate in the Jefferies Healthcare Conference
NATICK, Mass. -- May 30, 2023 – Allurion, a...
First Multi-Center Study Combining the Allurion Program with GLP-1 Therapy Presented at the European Congress...
Allurion Presents Findings from Landmark Study Evaluating Fully Remote Weight Loss Coaching Program
Proprietar...
Allurion Announces Premium Tiers for the Virtual Care Suite and Launch of Proprietary “My Daily Action” Bundle...
Allurion Announces Appointment of MIT Distinguished Professor for AI and Health and MacArthur “Genius” Fellow
...Allurion named “Champion Partner” of the World Obesity Federation and official sponsor of World Obesity Day...
Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination...
Allurion Technologies’ training awarded World Obesity Federation SCOPE accreditation
- Allurion’s gold...
- The world’s first and only procedureless gastric balloon receives approval from Brazilian Health...
New Delhi, 06 Sep 2022:
Allurion, a company dedicated to ending obesity, has launched the Allurion...
- Company launches the Allurion Iris™ Artificial Intelligence Platform and introduces Success Predictor, a...
Company announces approval of the Allurion Balloon in Canada, Mexico, Australia, and India where approximately...